AbbVie Inc.
ABBVNYSE
$284.60
Last price · USD
- Market cap
- $504.9B
- P/E
- 120.1x
- EV / EBITDA
- 32.3x
- P/S
- 8.3x
- FCF yield
- 3.5%
- Div. yield
- 2.31%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
AbbVie Inc. cash flow statement
Annual · USD millions except per-share data · 37 lines
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | CAGR | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | 4,226 | 4,286 | 4,820 | 11,845 | 11,549 | -22.2% | |
| Depreciation & amortization | 8,139 | 8,386 | 8,698 | 8,467 | 8,521 | -1.1% | |
| Deferred income tax | (492) | (1,449) | (2,889) | (1,931) | (898) | — | |
| Stock-based compensation | 955 | 911 | 747 | 671 | 692 | +8.4% | |
| Change in working capital | (2,362) | (2,782) | 2,813 | (258) | (1,322) | — | |
| Accounts receivables | (1,490) | 207 | 66 | (1,455) | (1,321) | — | |
| Inventory | (234) | (319) | (417) | (686) | (142) | — | |
| Accounts payables | 951 | 177 | 3,840 | 1,605 | 1,628 | -12.6% | |
| Other working capital | (1,589) | (2,847) | (676) | 278 | (1,487) | — | |
| Other non-cash items | 8,604 | 9,454 | 8,650 | 6,149 | 4,235 | +19.4% | |
| Net cash from operating activities | 19,030 | 18,806 | 22,839 | 24,943 | 22,777 | -4.4% | |
| Operating cash flow | 19,030 | 18,806 | 22,839 | 24,943 | 22,777 | -4.4% | |
| Investing activities | |||||||
| Investments in PP&E | (1,214) | (974) | (777) | (695) | (787) | — | |
| Capital expenditure | (1,214) | (974) | (777) | (695) | (787) | — | |
| Acquisitions, net | (204) | (17,493) | (1,223) | (794) | (1,902) | — | |
| Purchases of investments | (35) | (73) | (77) | (1,438) | (119) | — | |
| Sales / maturities of investments | 76 | 555 | 55 | 1,530 | 98 | -6.2% | |
| Other investing activities | (5,266) | (2,835) | 13 | 774 | 366 | — | |
| Net cash from investing activities | (6,643) | (20,820) | (2,009) | (623) | (2,344) | — | |
| Financing activities | |||||||
| Net debt issuance | (327) | 7,350 | (4,149) | (12,433) | (8,414) | — | |
| Short-term net debt issuance | 2,499 | 0 | 0 | 0 | 0 | — | |
| Long-term net debt issuance | (2,826) | 7,350 | (4,149) | (12,433) | (8,414) | — | |
| Net stock issuance | (808) | (1,708) | (1,972) | (1,487) | (934) | — | |
| Common stock issuance | 172 | 0 | 0 | 0 | 0 | — | |
| Common stock repurchased | (980) | (1,708) | (1,972) | (1,487) | (934) | — | |
| Net common stock issuance | (808) | (1,708) | (1,972) | (1,487) | (934) | — | |
| Common dividends paid | (11,657) | (11,025) | (10,539) | (10,043) | (9,261) | — | |
| Net dividends paid | (11,657) | (11,025) | (10,539) | (10,043) | (9,261) | — | |
| Other financing activities | 68 | 172 | (562) | (840) | (430) | — | |
| Net cash from financing activities | (12,724) | (5,211) | (17,222) | (24,803) | (19,039) | — | |
| Cash summary | |||||||
| Effect of forex changes on cash | 42 | (65) | 5 | (62) | (97) | — | |
| Net change in cash | (295) | (7,290) | 3,613 | (545) | 1,297 | — | |
| Cash at beginning of period | 5,524 | 12,814 | 9,201 | 9,746 | 8,449 | -10.1% | |
| Cash at end of period | 5,229 | 5,524 | 12,814 | 9,201 | 9,746 | -14.4% | |
| Free cash flow | 17,816 | 17,832 | 22,062 | 24,248 | 21,990 | -5.1% | |
| Income taxes paid | 0 | 4,064 | 4,702 | 2,988 | 3,648 | — | |
| Interest paid | 0 | 2,811 | 2,469 | 2,546 | 2,712 | — | |